NCT06238219

Management of Neuromuscular Blocking Agents and Their Antagonism

Clinical Practice Survey on the Management of Neuromuscular Blocking Agents and Their Antagonism During General Anesthesia

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 3,000 (estimated)
• Sponsor: Erasme University Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Neuromuscular blocking agents (NMBA) are commonly used in clinical practice during general anesthesia to facilitate induction, intubation and surgery. Some studies have shown that their use can be deleterious if not codified. Recent recommendations concerning their use and antagonization were published in 2023. Research hypothesis: Using a single-center, retrospective practice study, we aim to analyze whether the 2023 ASA and ESAIC recommendations are being implemented regarding the use of neuromuscular blocking agents.

Conditions

• Neuromuscular Blocking Agents
• Neuromuscular Monitoring

Interventions

Type	Name	Description
DRUG	Neuromuscular Blocking Agent	Administration of any neuromuscular blocking agent for surgery under general anesthesia

Timeline

• Start date: 2024-04-17
• Primary completion: 2024-11-30
• Completion: 2024-12-31
• First posted: 2024-02-02
• Last updated: 2024-04-19

Locations

1 site across 1 country: Belgium